193 related articles for article (PubMed ID: 26768345)
1. Adverse effects after the use of JWH-210 - a case series from the EU Spice II plus project.
Hermanns-Clausen M; Kithinji J; Spehl M; Angerer V; Franz F; Eyer F; Auwärter V
Drug Test Anal; 2016 Oct; 8(10):1030-1038. PubMed ID: 26768345
[TBL] [Abstract][Full Text] [Related]
2. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings.
Hermanns-Clausen M; Kneisel S; Szabo B; Auwärter V
Addiction; 2013 Mar; 108(3):534-44. PubMed ID: 22971158
[TBL] [Abstract][Full Text] [Related]
3. Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls.
Möller I; Wintermeyer A; Bender K; Jübner M; Thomas A; Krug O; Schänzer W; Thevis M
Drug Test Anal; 2011 Sep; 3(9):609-20. PubMed ID: 20872894
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic properties of the synthetic cannabinoid JWH-018 in oral fluid after inhalation.
Toennes SW; Geraths A; Pogoda W; Paulke A; Wunder C; Theunissen EL; Ramaekers JG
Drug Test Anal; 2018 Apr; 10(4):644-650. PubMed ID: 28967189
[TBL] [Abstract][Full Text] [Related]
5. Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice.
Vigolo A; Ossato A; Trapella C; Vincenzi F; Rimondo C; Seri C; Varani K; Serpelloni G; Marti M
Neuropharmacology; 2015 Aug; 95():68-82. PubMed ID: 25769232
[TBL] [Abstract][Full Text] [Related]
6. Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures.
Grigoryev A; Savchuk S; Melnik A; Moskaleva N; Dzhurko J; Ershov M; Nosyrev A; Vedenin A; Izotov B; Zabirova I; Rozhanets V
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 May; 879(15-16):1126-36. PubMed ID: 21481654
[TBL] [Abstract][Full Text] [Related]
7. Characterization of in vitro metabolites of JWH-018, JWH-073 and their 4-methyl derivatives, markers of the abuse of these synthetic cannabinoids.
Gambaro V; Arnoldi S; Bellucci S; Casagni E; Dell'Acqua L; Fumagalli L; Pallavicini M; Roda G; Rusconi C; Valoti E
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Apr; 957():68-76. PubMed ID: 24657413
[TBL] [Abstract][Full Text] [Related]
8. Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants.
Patton AL; Seely KA; Yarbrough AL; Fantegrossi W; James LP; McCain KR; Fujiwara R; Prather PL; Moran JH; Radominska-Pandya A
Biochem Biophys Res Commun; 2018 Apr; 498(3):597-602. PubMed ID: 29522717
[TBL] [Abstract][Full Text] [Related]
9. Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in 'herbal mixtures' using LC-MS/MS techniques.
Hutter M; Broecker S; Kneisel S; Auwärter V
J Mass Spectrom; 2012 Jan; 47(1):54-65. PubMed ID: 22282090
[TBL] [Abstract][Full Text] [Related]
10. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.
Rajasekaran M; Brents LK; Franks LN; Moran JH; Prather PL
Toxicol Appl Pharmacol; 2013 Jun; 269(2):100-8. PubMed ID: 23537664
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of synthetic cannabinoids in U.S. athletes: initial findings.
Heltsley R; Shelby MK; Crouch DJ; Black DL; Robert TA; Marshall L; Bender CL; DePriest AZ; Colello MA
J Anal Toxicol; 2012 Oct; 36(8):588-93. PubMed ID: 22872465
[TBL] [Abstract][Full Text] [Related]
12. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.
Brents LK; Reichard EE; Zimmerman SM; Moran JH; Fantegrossi WE; Prather PL
PLoS One; 2011; 6(7):e21917. PubMed ID: 21755008
[TBL] [Abstract][Full Text] [Related]
13. Synthetic cannabinoid JWH-018 and psychosis: an explorative study.
Every-Palmer S
Drug Alcohol Depend; 2011 Sep; 117(2-3):152-7. PubMed ID: 21316162
[TBL] [Abstract][Full Text] [Related]
14. Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.
Thomas BF; Lefever TW; Cortes RA; Grabenauer M; Kovach AL; Cox AO; Patel PR; Pollard GT; Marusich JA; Kevin RC; Gamage TF; Wiley JL
J Pharmacol Exp Ther; 2017 Apr; 361(1):162-171. PubMed ID: 28087785
[TBL] [Abstract][Full Text] [Related]
15. Metabolic patterns of JWH-210, RCS-4, and THC in pig urine elucidated using LC-HR-MS/MS: Do they reflect patterns in humans?
Schaefer N; Helfer AG; Kettner M; Laschke MW; Schlote J; Ewald AH; Meyer MR; Menger MD; Maurer HH; Schmidt PH
Drug Test Anal; 2017 Apr; 9(4):613-625. PubMed ID: 27328899
[TBL] [Abstract][Full Text] [Related]
16. Detection Times of Carboxylic Acid Metabolites of the Synthetic Cannabinoids JWH-018 and JWH-073 in Human Urine.
Hegstad S; Westin AA; Spigset O
J Anal Toxicol; 2015 May; 39(4):280-6. PubMed ID: 25737323
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018.
Su MK; Seely KA; Moran JH; Hoffman RS
Clin Pharmacol Ther; 2015 Jun; 97(6):562-4. PubMed ID: 25788107
[TBL] [Abstract][Full Text] [Related]
18. Detection and tentative identification of urinary phase I metabolites of phenylacetylindole cannabimimetics JWH-203 and JWH-251, by GC-MS and LC-MS/MS.
Kavanagh P; Grigoryev A; Melnik A; Savchuk S; Simonov A; Rozhanets V
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Sep; 934():102-8. PubMed ID: 23917406
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.
Wiley JL; Lefever TW; Marusich JA; Grabenauer M; Moore KN; Huffman JW; Thomas BF
Neuropharmacology; 2016 Nov; 110(Pt A):143-153. PubMed ID: 27449567
[TBL] [Abstract][Full Text] [Related]
20. Natural (∆
Malyshevskaya O; Aritake K; Kaushik MK; Uchiyama N; Cherasse Y; Kikura-Hanajiri R; Urade Y
Sci Rep; 2017 Sep; 7(1):10516. PubMed ID: 28874764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
